Isabel Steinhauser

TL;DR: It could be shown that the kinetics of particle degradation was dependent on the degree of particle stabilisation, which will influence drug release after cellular accumulation of HSA nanoparticles.

TL;DR: Biological activity was confirmed under cell culture conditions: antibody-conjugated nanoparticles showed a specific targeting to HER2-overexpressing cells with cellular uptake by receptor-mediated endocytosis, which provides the basis for the development of stable and biological active carrier systems for directed targeting of tumour cells using trastuzumab- Conjugated HSA nanoparticles.

TL;DR: This is the first report of ASO-loaded HSA nanoparticles prepared by heat denaturation, where an impact on gene expression could be observed and the data provide the basis for the further development of carrier systems for ASOs to reduce off-target effects evoked by systemically administered ASOs and to achieve a better penetration into primary and metastatic target cells.

TL;DR: This is the first report about ASO-loaded HSA nanoparticles, where an impact on gene expression could be observed, and the data provide the basis for the further development of carrier systems for Plk1-specific ASOs to reduce off-target effects evoked by systemically administered ASOs and to achieve a better penetration into primary and metastatic target cells.

TL;DR: Human serum albumin nanoparticles conjugated to trastuzumab for a cell type–specific targeting of human epidermal growth factor receptor 2 (HER2)-overexpressing cells were developed with incorporated expression plasmids for small hairpin RNAs targeting polo-like kinase 1 (Plk1).